{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T07:56:50Z","timestamp":1767772610971,"version":"build-2065373602"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s10787-025-01971-z","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T06:51:41Z","timestamp":1759128701000},"page":"5895-5907","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of Mirikizumab in the treatment of moderate to severe inflammatory bowel diseases: a systematic review and updated meta-analysis"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7913-2927","authenticated-orcid":false,"given":"Joel Gabin Konlack","family":"Mekontso","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph Yvan","family":"Bena Nnang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel G. J.","family":"Fodop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bishoy I. B.","family":"Elkoumes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guy Loic Nguefang","family":"Tchoukeu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anifatou B.","family":"Kortim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ticha B. T.","family":"Tembi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akil","family":"Olliverre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jarin","family":"Prasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Trillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"issue":"1","key":"1971_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2468-1253(19)30333-4","volume":"5","author":"S Alatab","year":"2020","unstructured":"Alatab S, Sepanlou SG, Ikuta K et al (2020) The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol 5(1):17\u201330. https:\/\/doi.org\/10.1016\/S2468-1253(19)30333-4","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"18","key":"1971_CR2","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1002\/sim.1221","volume":"21","author":"B Baujat","year":"2002","unstructured":"Baujat B, Mah\u00e9 C, Pignon J, Hill C (2002) A graphical method for exploring heterogeneity in meta-analyses: application to a meta-analysis of 65 trials. Stat Med 21(18):2641\u20132652. https:\/\/doi.org\/10.1002\/sim.1221","journal-title":"Stat Med"},{"issue":"14","key":"1971_CR3","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1056\/NEJMra1907607","volume":"385","author":"DC Baumgart","year":"2021","unstructured":"Baumgart DC, Le Berre C (2021) Newer biologic and small-molecule therapies for inflammatory bowel disease. N Engl J Med 385(14):1302\u20131315. https:\/\/doi.org\/10.1056\/NEJMra1907607","journal-title":"N Engl J Med"},{"issue":"9853","key":"1971_CR4","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/S0140-6736(12)60026-9","volume":"380","author":"DC Baumgart","year":"2012","unstructured":"Baumgart DC, Sandborn WJ (2012) Crohn\u2019s disease. Lancet 380(9853):1590\u20131605. https:\/\/doi.org\/10.1016\/S0140-6736(12)60026-9","journal-title":"Lancet"},{"issue":"27","key":"1971_CR5","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1056\/NEJMra2002697","volume":"383","author":"JT Chang","year":"2020","unstructured":"Chang JT (2020) Pathophysiology of inflammatory bowel diseases. N Engl J Med 383(27):2652\u20132664. https:\/\/doi.org\/10.1056\/NEJMra2002697","journal-title":"N Engl J Med"},{"issue":"17","key":"1971_CR6","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000042123","volume":"104","author":"X Chen","year":"2025","unstructured":"Chen X, Si G, Li Y, Yuan X (2025) Efficacy and safety of Mirikizumab in the treatment of inflammatory bowel disease: a meta-analysis. Medicine (Baltimore) 104(17):e42123. https:\/\/doi.org\/10.1097\/MD.0000000000042123","journal-title":"Medicine (Baltimore)"},{"key":"1971_CR7","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjad212.1174","volume":"18","author":"L Chua","year":"2024","unstructured":"Chua L, Otani Y, Friedrich S, Durand F, Zhang X (2024) P1044 Mirikizumab pharmacokinetics and exposure-response in a phase 2 study in patients with moderately to severely active Crohn\u2019s disease. J Crohns Colitis 18:i1873. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjad212.1174","journal-title":"J Crohns Colitis"},{"issue":"3","key":"1971_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14031001","volume":"14","author":"M Colwill","year":"2025","unstructured":"Colwill M, Baillie S, Clough J et al (2025) Role of Mirikizumab in the treatment of Inflammatory Bowel Disease-From bench to bedside. J Clin Med 14(3):1001. https:\/\/doi.org\/10.3390\/jcm14031001","journal-title":"J Clin Med"},{"issue":"9","key":"1971_CR9","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1002\/eji.201242598","volume":"42","author":"AL Croxford","year":"2012","unstructured":"Croxford AL, Mair F, Becher B (2012) IL -23: one cytokine in control of autoimmunity. Eur J Immunol 42(9):2263\u20132273. https:\/\/doi.org\/10.1002\/eji.201242598","journal-title":"Eur J Immunol"},{"issue":"26","key":"1971_CR10","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","volume":"388","author":"G D\u2019Haens","year":"2023","unstructured":"D\u2019Haens G, Dubinsky M, Kobayashi T et al (2023) Mirikizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 388(26):2444\u20132455. https:\/\/doi.org\/10.1056\/NEJMoa2207940","journal-title":"N Engl J Med"},{"issue":"5804","key":"1971_CR11","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1126\/science.1135245","volume":"314","author":"RH Duerr","year":"2006","unstructured":"Duerr RH, Taylor KD, Brant SR et al (2006) A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314(5804):1461\u20131463. https:\/\/doi.org\/10.1126\/science.1135245","journal-title":"Science"},{"issue":"1","key":"1971_CR12","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1186\/s12876-025-03627-2","volume":"25","author":"MAA Elainein","year":"2025","unstructured":"Elainein MAA, ElSherefy SS, Yousef NM et al (2025) Efficacy and safety of Mirikizumab for ulcerative colitis: a systematic review and meta-analysis of randomized controlled trials. BMC Gastroenterol 25(1):307. https:\/\/doi.org\/10.1186\/s12876-025-03627-2","journal-title":"BMC Gastroenterol"},{"issue":"10470","key":"1971_CR13","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1016\/S0140-6736(24)01762-8","volume":"404","author":"M Ferrante","year":"2024","unstructured":"Ferrante M, D\u2019Haens G, Jairath V et al (2024) Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn\u2019s disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study. Lancet 404(10470):2423\u20132436. https:\/\/doi.org\/10.1016\/S0140-6736(24)01762-8","journal-title":"Lancet"},{"key":"1971_CR14","unstructured":"GRADEpro GDT (2024) GRADEpro Guideline Development Tool [Software]. Published online 2024. Available from gradepro.org."},{"issue":"10S","key":"1971_CR15","doi-asserted-by":"publisher","first-page":"S1007","DOI":"10.14309\/01.ajg.0001035004.02997.02","volume":"119","author":"N Hassan","year":"2024","unstructured":"Hassan N, Mohamed I, Mahmoud M et al (2024) S1409 Mirikizumab as an induction and maintenance therapy for ulcerative colitis: a systematic review and meta-analysis of randomized control trials. Am J Gastroenterol 119(10S):S1007\u2013S1008. https:\/\/doi.org\/10.14309\/01.ajg.0001035004.02997.02","journal-title":"Am J Gastroenterol"},{"key":"1971_CR16","volume-title":"Cochrane handbook for systematic reviews of interventions version 6.5 (Updated August 2024)","author":"J Higgins","year":"2024","unstructured":"Higgins J, Thomas J, Chandler J et al (2024) Cochrane handbook for systematic reviews of interventions version 6.5 (Updated August 2024). Cochrane"},{"issue":"6","key":"1971_CR17","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1136\/annrheumdis-2013-204741","volume":"73","author":"A Kavanaugh","year":"2014","unstructured":"Kavanaugh A, Ritchlin C, Rahman P et al (2014) Ustekinumab, an anti-IL-12\/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann Rheum Dis 73(6):1000\u20131006. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204741","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1971_CR18","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S2468-1253(21)00377-0","volume":"7","author":"JS Lasa","year":"2022","unstructured":"Lasa JS, Olivera PA, Danese S, Peyrin-Biroulet L (2022) Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol 7(2):161\u2013170. https:\/\/doi.org\/10.1016\/S2468-1253(21)00377-0","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"1971_CR19","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/ajg.2018.27","volume":"113","author":"GR Lichtenstein","year":"2018","unstructured":"Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE (2018) ACG clinical guideline: management of Crohn\u2019s disease in adults. Am J Gastroenterol 113(4):481\u2013517. https:\/\/doi.org\/10.1038\/ajg.2018.27","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"1971_CR20","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1093\/ecco-jcc\/jjad050","volume":"17","author":"F Magro","year":"2023","unstructured":"Magro F, Pai R, Kobayashi T et al (2023) Resolving histological inflammation in ulcerative colitis with mirikizumab in the LUCENT induction and maintenance trial programmes. J Crohns Colitis 17(9):1457\u20131470. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjad050","journal-title":"J Crohns Colitis"},{"issue":"9","key":"1971_CR21","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1016\/j.cgh.2023.11.010","volume":"22","author":"F Magro","year":"2024","unstructured":"Magro F, Protic M, De Hertogh G et al (2024) Effects of Mirikizumab on histologic resolution of Crohn\u2019s disease in a randomized controlled phase 2 trial. Clin Gastroenterol Hepatol 22(9):1878-1888.e10. https:\/\/doi.org\/10.1016\/j.cgh.2023.11.010","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"1971_CR22","doi-asserted-by":"publisher","first-page":"e0005","DOI":"10.1097\/HC9.0000000000000005","volume":"7","author":"CH Ng","year":"2023","unstructured":"Ng CH, Tang ASP, Xiao J et al (2023) Safety and tolerability of obeticholic acid in chronic liver disease: a pooled analysis of 1878 individuals. Hepatol Commun 7(3):e0005. https:\/\/doi.org\/10.1097\/HC9.0000000000000005","journal-title":"Hepatol Commun"},{"issue":"9853","key":"1971_CR23","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/S0140-6736(12)60150-0","volume":"380","author":"I Ord\u00e1s","year":"2012","unstructured":"Ord\u00e1s I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ (2012) Ulcerative colitis. Lancet 380(9853):1606\u20131619. https:\/\/doi.org\/10.1016\/S0140-6736(12)60150-0","journal-title":"Lancet"},{"key":"1971_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2020) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"1971_CR25","doi-asserted-by":"publisher","DOI":"10.2174\/1574886312666170616085228","author":"R Pereira","year":"2017","unstructured":"Pereira R, Faria R, Lago P, Torres T (2017) Infection and malignancy risk in patients treated with TNF inhibitors for immune-mediated inflammatory diseases. Curr Drug Saf. https:\/\/doi.org\/10.2174\/1574886312666170616085228","journal-title":"Curr Drug Saf"},{"issue":"2","key":"1971_CR26","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1093\/ibd\/izae166","volume":"31","author":"M Regueiro","year":"2025","unstructured":"Regueiro M, Fischer M, Bossuyt P et al (2025) Mirikizumab sustained impact on fatigue in patients with moderately to severely active Crohn\u2019s disease in the phase 2 AMAG study. Inflamm Bowel Dis 31(2):432\u2013441. https:\/\/doi.org\/10.1093\/ibd\/izae166","journal-title":"Inflamm Bowel Dis"},{"key":"1971_CR27","unstructured":"RevMan (2024) Review Manager (RevMan). Version (8.13.0). The Cochrane Collaboration. Published online December 18, 2024. Available at revman.cochrane.org"},{"issue":"3","key":"1971_CR28","doi-asserted-by":"publisher","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","volume":"114","author":"DT Rubin","year":"2019","unstructured":"Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD (2019) ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol 114(3):384\u2013413. https:\/\/doi.org\/10.14309\/ajg.0000000000000152","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"1971_CR29","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1053\/j.gastro.2019.08.043","volume":"158","author":"W Sandborn","year":"2020","unstructured":"Sandborn W, Ferrante M, Bhandari B et al (2020) Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis. Gastroenterology 158(3):537-549.e10. https:\/\/doi.org\/10.1053\/j.gastro.2019.08.043","journal-title":"Gastroenterology"},{"issue":"2","key":"1971_CR30","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1053\/j.gastro.2021.10.050","volume":"162","author":"BE Sands","year":"2022","unstructured":"Sands BE, Peyrin-Biroulet L, Kierkus J et al (2022) Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with Crohn\u2019s disease. Gastroenterology 162(2):495\u2013508. https:\/\/doi.org\/10.1053\/j.gastro.2021.10.050","journal-title":"Gastroenterology"},{"issue":"4","key":"1971_CR31","doi-asserted-by":"publisher","DOI":"10.1093\/crocol\/otad070","volume":"5","author":"BE Sands","year":"2023","unstructured":"Sands BE, Feagan BG, Hunter Gibble T et al (2023) Mirikizumab improves quality of life in patients with moderately-to-severely active ulcerative colitis: results from the phase 3 LUCENT-1 induction and LUCENT-2 maintenance studies. Crohns Colitis 360 5(4):otad070. https:\/\/doi.org\/10.1093\/crocol\/otad070","journal-title":"Crohns Colitis 360"},{"issue":"7","key":"1971_CR32","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1093\/ibd\/izae253","volume":"31","author":"BE Sands","year":"2025","unstructured":"Sands BE, D\u2019Haens G, Clemow DB et al (2025) Three-year efficacy and safety of mirikizumab following 152 weeks of continuous treatment for ulcerative colitis: results from the LUCENT-3 open-label extension study. Inflamm Bowel Dis 31(7):1876\u20131890. https:\/\/doi.org\/10.1093\/ibd\/izae253","journal-title":"Inflamm Bowel Dis"},{"key":"1971_CR33","volume-title":"GRADE handbook for grading quality of evidence and strength of recommendations. Updated October 2013","author":"H Sch\u00fcnemann","year":"2013","unstructured":"Sch\u00fcnemann H, Bro\u017cek J, Guyatt G, Oxman A (2013) GRADE handbook for grading quality of evidence and strength of recommendations. Updated October 2013. The GRADE Working Group"},{"key":"1971_CR34","volume-title":"Cochrane handbook for systematic reviews of interventions version 6.1 (Updated September 2020)","author":"H Sch\u00fcnemann","year":"2020","unstructured":"Sch\u00fcnemann H, Page M, Higgins J, Sterne J (2020) Chapter 13: assessing risk of bias due to missing results in a synthesis (last updated September 2020). In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (eds) Cochrane handbook for systematic reviews of interventions version 6.1 (Updated September 2020). Cochrane, Cham"},{"key":"1971_CR35","volume-title":"Cochrane handbook for systematic reviews of interventions version 6.5","author":"H Sch\u00fcnemann","year":"2024","unstructured":"Sch\u00fcnemann H, Higgins J, Vist G et al (2024) Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence [last updated August 2023]. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (eds) Cochrane handbook for systematic reviews of interventions version 6.5. Cochrane"},{"key":"1971_CR36","volume-title":"Cochrane handbook for systematic reviews of interventions version 6.5","author":"H Sch\u00fcnemann","year":"2024","unstructured":"Sch\u00fcnemann H, Vist G, Higgins J et al (2024) Chapter 15: Interpreting results and drawing conclusions [last updated August 2024]. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (eds) Cochrane handbook for systematic reviews of interventions version 6.5. Cochrane"},{"issue":"6","key":"1971_CR37","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1093\/ecco-jcc\/jjy004","volume":"12","author":"S Singh","year":"2018","unstructured":"Singh S, George J, Boland BS, Vande Casteele N, Sandborn WJ (2018) Primary non-response to tumor necrosis factor antagonists is associated with inferior response to second-line biologics in patients with inflammatory bowel diseases: a systematic review and meta-analysis. J Crohns Colitis 12(6):635\u2013643. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjy004","journal-title":"J Crohns Colitis"},{"issue":"jul22 1","key":"1971_CR38","doi-asserted-by":"publisher","first-page":"d4002","DOI":"10.1136\/bmj.d4002","volume":"343","author":"JAC Sterne","year":"2011","unstructured":"Sterne JAC, Sutton AJ, Ioannidis JPA et al (2011) Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 343(jul22 1):d4002\u2013d4002. https:\/\/doi.org\/10.1136\/bmj.d4002","journal-title":"BMJ"},{"key":"1971_CR39","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"issue":"7","key":"1971_CR40","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41575-023-00768-1","volume":"20","author":"B Verstockt","year":"2023","unstructured":"Verstockt B, Salas A, Sands BE et al (2023) IL-12 and IL-23 pathway inhibition in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol 20(7):433\u2013446. https:\/\/doi.org\/10.1038\/s41575-023-00768-1","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"1971_CR41","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/jrsm.11","volume":"1","author":"W Viechtbauer","year":"2010","unstructured":"Viechtbauer W, Cheung MWL (2010) Outlier and influence diagnostics for meta-analysis. Res Synth Methods 1(2):112\u2013125. https:\/\/doi.org\/10.1002\/jrsm.11","journal-title":"Res Synth Methods"},{"issue":"10","key":"1971_CR42","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1002\/cpdd.1449","volume":"13","author":"J Xu","year":"2024","unstructured":"Xu J, Xie R, Ji Y et al (2024) Safety and pharmacokinetics of single-dose mirikizumab in Chinese healthy participants: results from a phase 1 study. Clin Pharmacol Drug Dev 13(10):1143\u20131150. https:\/\/doi.org\/10.1002\/cpdd.1449","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"1","key":"1971_CR43","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2025.2455536","volume":"57","author":"H Yang","year":"2025","unstructured":"Yang H, An T, Zhao Y, Shi X, Wang B, Zhang Q (2025) Cardiovascular safety of Janus kinase inhibitors in inflammatory bowel disease: a systematic review and network meta-analysis. Ann Med 57(1):2455536. https:\/\/doi.org\/10.1080\/07853890.2025.2455536","journal-title":"Ann Med"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-025-01971-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-025-01971-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-025-01971-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T19:04:52Z","timestamp":1761332692000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-025-01971-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":43,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1971"],"URL":"https:\/\/doi.org\/10.1007\/s10787-025-01971-z","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"type":"print","value":"0925-4692"},{"type":"electronic","value":"1568-5608"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"assertion":[{"value":"2 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors of this review declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study is a meta-analysis of previously published data and does not involve any new data collection from human participants or animals. Therefore, ethical approval and informed consent were not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}},{"value":"We used Paperpal AI to review and enhance the manuscript\u2019s grammar, spelling, and punctuation while ensuring the scientific content and interpretations remained unchanged.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"AI use statement"}}]}}